IPO Update: Returns Halved As Two Biopharmas Go Public In April; Unity Is May's First

Only two drug developers launched offerings in April and the average 2018 IPO return was just 9% – half the first quarter average – at the end of last month. Unity's May 1 offering was the 17th biopharma IPO this year.